Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.89 GBX | +2.37% | -0.26% | -8.47% |
Apr. 15 | Fusion Antibodies inks commercial contract for OptiPhage library | AN |
Apr. 15 | Fusion Antibodies Secures Contract to Set Up OptiPhage Library | MT |
Sales 2024 * | 1.15M 1.43M | Sales 2025 * | - | Capitalization | 3.62M 4.52M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.25M | Net income 2025 * | - | EV / Sales 2024 * | 3.15 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.36
x | P/E ratio 2025 * |
-
| Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.63% |
1 day | +2.37% | ||
1 week | -0.26% | ||
Current month | +3.73% | ||
1 month | +1.04% | ||
3 months | -33.79% | ||
6 months | -32.35% | ||
Current year | -8.47% |
Managers | Title | Age | Since |
---|---|---|---|
Adrian Kinkaid
CEO | Chief Executive Officer | 57 | 22-08-14 |
Stephen Smyth
DFI | Director of Finance/CFO | 49 | 23-08-23 |
Simon Douglas
CHM | Chairman | 65 | 05-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Colin Walsh
BRD | Director/Board Member | 68 | 06-12-31 |
Simon Douglas
CHM | Chairman | 65 | 05-12-31 |
Richard Buick
CTO | Chief Tech/Sci/R&D Officer | 47 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 3.89 | +2.37% | 100 127 |
24-04-17 | 3.8 | 0.00% | 163,284 |
24-04-16 | 3.8 | -2.56% | 1,362,731 |
24-04-15 | 3.9 | -3.70% | 2,975,946 |
24-04-12 | 4.05 | +3.85% | 1,652,389 |
Delayed Quote London S.E., April 18, 2024 at 03:16 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.47% | 4.51M | |
-1.78% | 41.36B | |
+44.81% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
-2.67% | 11.82B | |
+24.76% | 11.85B | |
+7.01% | 11.07B |
- Stock Market
- Equities
- FAB Stock